The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.
The FDA approved T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, based on DESTINY-Breast09 trial results. The combination therapy reduced disease progression or death risk by 44% ...
The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the ...
In this video, Erica L. Mayer, MD, MPH, discusses data from the phase 3 lidERA trial demonstrating that giredestrant improved disease-free survival in early-stage, hormone receptor-positive, ...
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Distractify on MSNOpinion
Psychedelic researcher questions industry's rush to market
Johns Hopkins trial veteran warns venture capital threatens therapeutic integrity as psilocybin nears FDA approval ...
Booking Health, a leading platform for international medical travel, announced today the release of its 2026 rankings of Germany’s most trusted cancer hospitals. These certified oncology centers are ...
Stage 4 metastatic breast cancer presents significant emotional and psychological challenges, requiring patients to adapt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback